OS01.7.A AGE AND SEX AS RISK FACTORS FOR HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN GLIOMA PATIENTS: POOLED ANALYSES OF CLINICAL TRIALS FROM THE CODAGLIO 2.0 DATABASE

Abstract BACKGROUND The effect of age and sex on differences in health-related quality of life (HRQoL) is still debated, with limited available studies hampered by small sample size, lack of longitudinal analysis, and contradictory evidence. We investigated if age and sex are independent risk factors for HRQoL outcomes in patients with glioma. MATERIAL AND METHODS Using the EORTC QLQ-C30 and QLQ-BN20 questionnaires, we collected data on HRQoL from patients with glioma who participated in 16 randomized trials included in the CODAGLIO 2.0 database. We compared the mean HRQoL scores between patients at baseline and the general population in 8 scales: physical, social, role, and cognitive functioning; pain, fatigue, communication, and seizures. Furthermore, we identified which factors, including sex and age, had clinically relevant associations with HRQoL using a linear mixed model (LMM). Clinically relevant changes were interpreted using anchor-based minimally important differences. RESULTS We included 4301 glioma patients. In stratified descriptive statistics, male and female glioma patients did not differ significantly across all age groups in all selected HRQoL scales. Compared with the general population, glioma patients had statistically and clinically relevant worse HRQoL outcomes at the baseline. In LMM, patients >60 years old had statistically significant associations with lower physical functioning (-2.40; 95% confidence interval (CI) -4.14 to -0.71), higher social (4.88; 95% CI 2.68 to 7.30) and role functioning (3.79; 95% CI 1.39 to 6.16), and less fatigue (-3.43; 95% CI -5.44 to -1.33) and pain (-4.56; 95% CI -6.18 to -2.93) within 3 months of follow-up, compared to those ≤60 years old, while no significant change was seen for cognitive functioning, communication deficits, and seizures. Additionally, female patients, compared to male patients, had significant associations with lower physical (-4.35; 95% CI -5.73 to -2.86) and social (-2.03; 95% CI -3.98 to -0.06) functioning and showed more fatigue (4.90; 95% CI 3.16 to 6.50) and pain (3.37; 95% CI 1.70 to 4.97), whereas no significant change was seen for role and cognitive functioning, communication deficits, and seizures. None of the associations between HRQoL and age and sex reached clinical relevance. However, WHO performance status ≥1 compared to 0 was both statistically and clinically relevant in 5/8 scales and only statistically significant in 3/8 scales assessed. CONCLUSION Patients with glioma have clinically relevant worse HRQoL outcomes at the baseline compared to the general population. However, age and sex are not independently associated with HRQoL to a clinically relevant extent in patients with glioma. Other variables with a clinically meaningful association, such as performance status, seem to play a more relevant role in determining a patient’s HRQoL.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-10-01
DOI
https://doi.org/10.1093/neuonc/noaf193.033
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

OS01.7.A AGE AND SEX AS RISK FACTORS FOR HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN GLIOMA PATIENTS: POOLED ANALYSES OF CLINICAL TRIALS FROM THE CODAGLIO 2.0 DATABASE

Paul M. Clément, Mirjam Renovanz, Caroline Hertler, Martin J. van den Bent et al.
Neuro-Oncology
Glioma Diagnosis and Treatment
article

OS01.7.A AGE AND SEX AS RISK FACTORS FOR HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN GLIOMA PATIENTS: POOLED ANALYSES OF CLINICAL TRIALS FROM THE CODAGLIO 2.0 DATABASE

Paul M. Clément, Mirjam Renovanz, Caroline Hertler, Martin J. van den Bent, Kathy Oliver, Michael Weller, Clemens Seidel, Linda Dirven, Matthijs van der Meulen, Claudia Panciroli, Corneel Coens, Thierry Gorlia, Roger Stupp, Andrea Talacchi, Christine Marosi, Martin Taphoorn, Emilie Le Guen, Annika Malmström, Florence Keime-Guibert, Ulrich Herrlinger, Lyn‐li Lim, Andrea Pace, J.C. Reijneveld, Olivier Chinot, Brigitta G. Baumert, Wolfgang Wick, Francesca Martinelli, Alba A. Brandes, JAF Koekkoek, Neil K Aaronson, O A Edeh-Asogwa
article en

Abstract

Abstract BACKGROUND The effect of age and sex on differences in health-related quality of life (HRQoL) is still debated, with limited available studies hampered by small sample size, lack of longitudinal analysis, and contradictory evidence. We investigated if age and sex are independent risk factors for HRQoL outcomes in patients with glioma. MATERIAL AND METHODS Using the EORTC QLQ-C30 and QLQ-BN20 questionnaires, we collected data on HRQoL from patients with glioma who participated in 16 randomized trials included in the CODAGLIO 2.0 database. We compared the mean HRQoL scores between patients at baseline and the general population in 8 scales: physical, social, role, and cognitive functioning; pain, fatigue, communication, and seizures. Furthermore, we identified which factors, including sex and age, had clinically relevant associations with HRQoL using a linear mixed model (LMM). Clinically relevant changes were interpreted using anchor-based minimally important differences. RESULTS We included 4301 glioma patients. In stratified descriptive statistics, male and female glioma patients did not differ significantly across all age groups in all selected HRQoL scales. Compared with the general population, glioma patients had statistically and clinically relevant worse HRQoL outcomes at the baseline. In LMM, patients >60 years old had statistically significant associations with lower physical functioning (-2.40; 95% confidence interval (CI) -4.14 to -0.71), higher social (4.88; 95% CI 2.68 to 7.30) and role functioning (3.79; 95% CI 1.39 to 6.16), and less fatigue (-3.43; 95% CI -5.44 to -1.33) and pain (-4.56; 95% CI -6.18 to -2.93) within 3 months of follow-up, compared to those ≤60 years old, while no significant change was seen for cognitive functioning, communication deficits, and seizures. Additionally, female patients, compared to male patients, had significant associations with lower physical (-4.35; 95% CI -5.73 to -2.86) and social (-2.03; 95% CI -3.98 to -0.06) functioning and showed more fatigue (4.90; 95% CI 3.16 to 6.50) and pain (3.37; 95% CI 1.70 to 4.97), whereas no significant change was seen for role and cognitive functioning, communication deficits, and seizures. None of the associations between HRQoL and age and sex reached clinical relevance. However, WHO performance status ≥1 compared to 0 was both statistically and clinically relevant in 5/8 scales and only statistically significant in 3/8 scales assessed. CONCLUSION Patients with glioma have clinically relevant worse HRQoL outcomes at the baseline compared to the general population. However, age and sex are not independently associated with HRQoL to a clinically relevant extent in patients with glioma. Other variables with a clinically meaningful association, such as performance status, seem to play a more relevant role in determining a patient’s HRQoL.

Neuro-OncologyVol. 27(Supplement_3)
Linköping University (SE), European Organisation for Research and Treatment of Cancer (NL), Centre National de la Recherche Scientifique (FR), Loyola University Medical Center (US), University of Bonn (DE), Leipzig University of Applied Sciences (DE), University of Zurich (CH), Heidelberg University (DE), Azienda Ospedaliera San Giovanni Addolorata (IT), Dutch Cancer Society (NL), Leiden University Medical Center (NL), University Hospital Heidelberg (DE), Centre Hospitalier Universitaire Vaudois (CH), Brain Tumour Charity (GB), The Netherlands Cancer Institute (NL), Institut de Neurophysiopathologie (FR), University Hospital of Zurich (CH), Institut Català d'Oncologia (ES), Oncode Institute (NL), Istituto delle Scienze Neurologiche di Bologna (IT), European Organisation for Research and Treatment of Cancer (BE), University Children's Hospital Tübingen (DE), Bernstein Center for Computational Neuroscience Tübingen (DE), National Cancer Institute (MY), Kantonsspital Graubünden (CH), Institut de Relations Internationales et Stratégiques (FR), Erasmus MC Cancer Institute (NL), Amsterdam University Medical Centers (NL), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Medical University of Vienna (AT), University of Amsterdam (NL), Amsterdam UMC Location Vrije Universiteit Amsterdam (NL), Leipzig University (DE), University of Lausanne (CH), KU Leuven (BE)
Openalex Percentile: Top 63%
Glioma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.